Composition comprising pip4k2c inhibitor as active ingredient for treatment of cancer

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising a PIP4K2C inhibitor as an active ingredient. The present invention provides a composition for efficient and radical treatment of cancer by discovering PIP4K2C as a new treatment target for cancer, which exhibits a high recurrence rate and is difficult to radically treat, and selecting a drug that inhibits PIP4K2C among known anticancer drugs.

1 - 13 . (canceled) 
     
     
         14 . A method for preventing or treating cancer comprising a step of administering a PIP4K2C inhibitor as an active ingredient to a subject. 
     
     
         15 . The method according to  claim 14 , wherein the cancer is selected from the group consisting of ovarian cancer, rhabdomyosarcoma, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, breast cancer, cervical cancer, thyroid cancer, parathyroid cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, biliary tract cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hematological cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head cancer, uterine cancer, rectal cancer, brain tumor, perianal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine cancer, endocrine adenocarcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, cancer of ureter, renal cell carcinoma, renal pelvic carcinoma, central nervous system (CNS) tumor, primary CNS lymphoma, spinal cord tumor, brainstem glioma, and pituitary adenoma. 
     
     
         16 . The method according to  claim 14 , wherein the PIP4K2C inhibitor comprises an antibody or antigen-binding fragment thereof that specifically binds to PIP4K2C, an aptamer that specifically binds to PIP4K2C, a nucleic acid molecule that inhibits expression of a nucleotide encoding PIP4K2C, or a small molecule compound that inhibits expression of PIP4K2C. 
     
     
         17 . The method according to  claim 16 , wherein the PIP4K2C inhibitor further comprises at least one small molecule compound selected from the group consisting of dutasteride, aprepitant, ivacaftor, adapalene, and pharmaceutically acceptable salts thereof. 
     
     
         18 . A method for screening a composition for preventing or treating cancer comprising steps of:
 (a) bringing a test substance into contact with a biological sample containing cells expressing PIP4K2C; and   (b) measuring an activity or expression level of PIP4K2C or measuring a viability or proliferation rate of the cells expressing PIP4K2C,   wherein, when the activity or expression level of PIP4K2C decreases or when the viability or proliferation rate of the cells expressing PIP4K2C decreases, the test substance is determined to be a composition for preventing or treating cancer.   
     
     
         19 . The method according to  claim 18 , wherein the biological sample is selected from the group consisting of whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, pelvic fluids, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cells, tissue, tissue-derived cells, cell extract, and cerebrospinal fluid. 
     
     
         20 . A composition for diagnosing cancer comprising, as an active ingredient, an agent for measuring an expression level of PIP4K2C protein or a gene encoding the same. 
     
     
         21 . The composition according to  claim 20 , wherein the agent for measuring the expression level of the PIP4K2C protein is an antibody or antigen-binding fragment thereof that specifically binds to the PIP4K2C protein, an aptamer that specifically binds to PIP4K2C, or a small molecule compound that inhibits expression of PIP4K2C. 
     
     
         22 . The composition according to  claim 20 , wherein the agent for measuring the expression level of the gene encoding the PIP4K2C protein is a primer or probe that specifically binds to a nucleic acid molecule of the gene.